We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma.
- Authors
Veeder, Michael H.; Jett, James R.; Su, John Q.; Mailliard, James A.; Foley, John F.; Dalton, Robert J.; Etzell, Paul S.; Marschke, Robert F.; Kardinal, Carl G.; Maksymiuk, Andrew W.; Ebbert, Larry P.; Tazelaar, Henry D.; Witrak, Geof A.; Veeder, M H; Jett, J R; Su, J Q; Mailliard, J A; Foley, J F; Dalton, R J; Etzell, P S
- Abstract
<bold>Background: </bold>In an effort to confirm the efficacy of mitomycin C against metastatic squamous cell lung carcinoma and to compare the efficacy of single-agent therapy with a combination containing cisplatin, the authors conducted a randomized Phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin (MVP).<bold>Methods: </bold>All patients had advanced squamous cell lung carcinoma, and survival was the primary end point. There were 133 eligible patients who received either mitomycin C alone (n = 64) or MVP (n = 69). The two groups were similar with respect to performance score, disease status, age, sex, and stage.<bold>Results: </bold>The major objective response rates were 30% (95% confidence interval [CI], 18-41%) and 43% (95% CI, 32-55%) for mitomycin C alone and MVP, respectively (P = 0.1). The median time to progression was 83 days for mitomycin C alone, compared with 119 days for MVP (P = 0.026). The median survival time was 114 days for mitomycin C and 163 days for MVP (P = 0.09). The 1-year survival rates were equivalent. Myelosuppression was the major toxicity, and there were significantly greater leukocyte nadirs with MVP therapy (P < 0.001).<bold>Conclusion: </bold>Mitomycin C has antitumor activity against squamous cell lung carcinoma when used alone or in combination with MVP. The regimen containing cisplatin had marginally increased activity that did not translate into a clinically significant survival advantage.
- Publication
Cancer (0008543X), 1992, Vol 70, Issue 9, p2281
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/1097-0142(19921101)70:9<2281::AID-CNCR2820700912>3.0.CO;2-9